Patents Examined by Michael J Schmitt
  • Patent number: 11944607
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: April 2, 2024
    Assignee: MediciNova, Inc.
    Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • Patent number: 11944631
    Abstract: Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof. Also provided herein are methods for treating cancer comprising administration the compositions, and uses of the compositions, e.g., for the treatment of cancer.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: April 2, 2024
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L Kutok, Howard M. Stern
  • Patent number: 11944629
    Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: April 2, 2024
    Assignee: MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARARATE MBH
    Inventor: Heiner Will
  • Patent number: 11925633
    Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: March 12, 2024
    Assignee: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Tadamasa Matsumoto, Masafumi Ihara, Satoshi Saito, Masanori Fukushima
  • Patent number: 11918586
    Abstract: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1 X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substitu
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: March 5, 2024
    Assignees: TORQUR AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Doriano Fabbro, Paul Hebeisen, Petra Hillmann-Wuellner, Anton Stuetz, John T. Seykora, Florent Beaufils
  • Patent number: 11911377
    Abstract: The present disclosure provides a method for treating hypertension by using a compound, wherein the compound is selected from the group consisting of: (E)-4-(3-(3-methyl benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione, (2R)-2-amino-3-(2,3-dihydro-1H-inden-1-yl)-N?-((E)-quinolin-7-ylmethylene)propane hydrazide, and a combination thereof. The present disclosure uses a small molecule compound (E)-4-(3-(3-methyl benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione, (2R)-2-amino-3-(2,3-dihydro-1H-inden-1-yl)-N?-((E)-quinolin-7-ylmethylene)propane hydrazide or a combination thereof, which can be developed as a therapeutic drug for lowering blood pressure, whether it is taken orally or injected.
    Type: Grant
    Filed: November 3, 2021
    Date of Patent: February 27, 2024
    Assignee: FU JEN CATHOLIC UNIVERSITY
    Inventors: Fu-Tien Chiang, Wei-Chao Chiu
  • Patent number: 11911360
    Abstract: The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: February 27, 2024
    Assignee: Lachesis Biosciences Limited
    Inventor: Timothy Matthias Morgan
  • Patent number: 11896710
    Abstract: The present disclosure provides methods of treating inflammation of the upper gastrointestinal tract, especially the esophagus, by administering an oral corticosteroid. In some cases, the methods include treating eosinophilic esophagitis (EoE) by administering an oral corticosteroid in an induction phase and a maintenance phase to improve peak eosinophilic counts and symptoms. In embodiments, the methods include treating EoE by administering the oral corticosteroid at nighttime and/or while the patient is lying down.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: February 13, 2024
    Assignee: Ellodi Pharmaceuticals, L.P.
    Inventors: Brian A. Meltzer, Gail M. Comer
  • Patent number: 11859252
    Abstract: The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 2, 2024
    Assignee: Genentech, Inc.
    Inventors: Christiaan Nicolaas Klijn, Shiva Malek, Ivana Yen
  • Patent number: 11850227
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: December 26, 2023
    Assignee: Axsome Malta Ltd.
    Inventor: Katayoun Zomorodi
  • Patent number: 11850226
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: December 26, 2023
    Assignee: Axsome Malta Ltd.
    Inventor: Katayoun Zomorodi
  • Patent number: 11850228
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: December 26, 2023
    Assignee: Axsome Malta Ltd.
    Inventor: Katayoun Zomorodi
  • Patent number: 11839599
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: December 12, 2023
    Assignee: Axsome Malta Ltd.
    Inventor: Katayoun Zomorodi
  • Patent number: 11839598
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: December 12, 2023
    Assignee: Axsome Malta Ltd.
    Inventor: Katayoun Zomorodi
  • Patent number: 11833137
    Abstract: The present invention includes substituted chromenones that are useful to inhibit the IRE1/XBP-1 pathway. In certain embodiments, the compounds of the invention inhibit IRE1's RNase activity. In other embodiments, the compounds of the invention are useful to treat or prevent a cancer that involve activation of the ER stress response. The invention also relates, in certain aspects, to the discovery that secretory IgM (sIgM) can orchestrate an immunosuppressive microenvironment by recruiting myeloid-derived suppressor cells (MDSCs) into different tumor models, such as but not limited to solid tumors (such as but not limited to lung cancer) and tumors that have high levels of secreted IgM. In certain embodiments, sIgM produced by B cells or CLL cells can contribute to the accumulation of MDSCs in a tumor. In other embodiments, inhibition of the IRE1/XBP-1 pathway can ablate, minimize, or reduce MDSC levels in a tumor.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: December 5, 2023
    Assignees: The Wistar Institute, University of South Florida
    Inventors: Chih-Chi Andrew Hu, Juan R. Del Valle
  • Patent number: 11819551
    Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: November 21, 2023
    Assignee: Avilar Therapeutics, Inc.
    Inventors: Mark George Saulnier, Jesse Jingyang Chen, Srinivasa Karra, Kevin Tyler Sprott, Jason Allan Wiles, Soumya Ray
  • Patent number: 11813232
    Abstract: The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: November 14, 2023
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Chengzhi Zhang, James Kerr
  • Patent number: 11806326
    Abstract: A method of treating Parkinson's Disease, Huntington's Disease and the like, diseases with abnormal dopamine-neuro-transmission, using small molecules administered systemically that penetrate into the central nervous system to inhibit the rate-limiting step of dopamine synthesis in the central nervous system, the conversion of L-tyrosine to L-3, 4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase along with its cofactors tetrahydrobiopterin and iron (Fe+).
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: November 7, 2023
    Inventor: Jonathan Sackner-Bernstein
  • Patent number: 11806344
    Abstract: Provided are a pharmaceutical composition comprising a mineralocorticoid receptor antagonist and use thereof. When the pharmaceutical composition is orally administered to a patient having chronic kidney disease in need thereof, the effective and safe AUC ranges from 188 ng*h/mL to 3173 ng*h/mL, with bioavailability of 50% or more in mammals. When the pharmaceutical composition is orally administered at a daily dose of 0.1 to 1.0 mg to treat chronic kidney disease, the AUC is controlled at a safe and effective level.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: November 7, 2023
    Assignee: KBP Biosciences Pte. Ltd.
    Inventors: Zhenhua Huang, Xiaocui Guo
  • Patent number: 11779571
    Abstract: The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: October 10, 2023
    Assignee: Salix Pharmaceuticals, Inc.
    Inventors: William Forbes, Enoch Bortey